Top Tweets for #vrci
⚡ TRADINGFLOOR AI // AI SELECTION
before the bell! Best riser was #0RPR: Ringkjoebing Landbobank A/S at 179.56% worst loser was #AZN: AstraZeneca PLCat -0.62% #0RPR #AAZ #VRCI #IOF #ECOB #NBS #PRTC #SOM #COG #AZN #AZN Tickers ordered by change follow/subscribe to get morning updates for fresh #AI selections see my early morning posts on the X for further info on each ticker #0RPR ▲ 179.56 BuyBack Ringkjoebing Landbobank A/S #AAZ ▲ 11.77 Results Anglo Asian Mining Plc #VRCI ▲ 11.11 Launch Verici Dx Plc #IOF ▲ 7.43 Results Iofina plc #ECOB ▲ 2.93 Agreement Eco Buildings Group plc #NBS ▲ 0.00 Offers Nationwide Building Society #PRTC ▼ -0.16 FDA PureTech Health plc #SOM ▼ -0.38 Agreement Somero Enterprise Inc #COG ▼ -0.44 Partner Cambridge Cognition Holdings Plc #AZN ▼ -0.62 Approvals AstraZeneca PLC #AZN ▼ -0.62 Approvals AstraZeneca PLC
🤝 #Partnership 🚀 #Launch 🔁 #Buyback 🤖 #AI 🤖 #TradingFloorAI
Full market intelligence in bio.
#VRCI
Albeit still a relatively small business (£5.1m mrkcap), @VericiDx certainly punches above it weight.
Today announcing that in Q4'26, it plans to launch a new "1st-in-class" genetic RNA blood test TranscripTx.
This diagnostic is specifically designed for the transplant community and can identify key variations in a person’s genes that are known to impact biological processes relevant to transplant patients.
Information that may accelerate new drug development, inform ongoing clinical trials and improve medical management protocols.
CEO Sara Barrington commenting: "This test underscores our commitment to pioneering personalised diagnostics in transplantation, maximising the strategic value of our clinical data while offering a vital new resource for therapeutic development and patient care."
Disclosure: @VericiDx is a @VOXmarkets client
Verici Dx expands diagnostics portfolio with Q4 launch of TranscripTx https://t.co/obVW8ppRIB
#VericiDX #VRCI $VRCI #Healthcare #HealthStocks #KidneyTransplant #AIHealth #FutureofMedicine #Innovation #AIM #UKequities #GrowthStocks #Investing #TranscripTx
⚡ TRADINGFLOOR AI // #VRCI
While the announcement highlights strategic value and potential for precision medicine, the company’s market cap (£7.9m) and enterprise value (£14.3m) are stale, and no financial impact or revenue forecast is disclosed | Market cap and enterprise value are stale, limiting valuation assessment No disclosed financial impact or revenue forecast from the launch Sector direction data unavailable No comparable prior launch event in 180‑day archive Risks and evidence gaps | Verici Dx PLC’s on 21 September 2026 announced the Q4 launch of TranscripTx™, described as a first‑in‑class genetic test designed for organ‑transplant patients | Valuation asymmetry is set to 0 as both market cap (£7.9 m) and enterprise value (£14.3 m) are stale | financing analysis not applicable Scientific backing from peer‑reviewed publications Executive endorsement provides credibility Lack of third‑party sales forecasts reduces confidence Fresh market cap and enterprise value not available Financing analysis not provided as event is not a funding round Sector context missing from point‑in‑time data Revenue or sales projections not disclosed | The novelty score is limited to +1 because the point‑in‑time context shows no comparable prior launch in the 180‑day archive | Financing cash impact is 0 because the event is not a capital raise and no proceeds or dilution are disclosed | Credibility receives +2 based on scientific backing and executive endorsement, though the absence of third‑party sales forecasts tempers confidence | Verici Dx PLC announced the Q4 launch of TranscripTx™, a first‑in‑class genetic test for transplant patients, leveraging AI and RNA diagnostics to detect clinically relevant variants | Sector relevance is 0 due to missing sector direction data | 72/100 | invalidation would arise if the test faced regulatory hurdles or failed to achieve commercial uptake | Baggers AI Score | The announcement states the test uses next‑generation sequencing of peripheral blood RNA, incorporates AI‑enabled gene selection, and can detect splice variants missed by cell‑free...
💸 #Revenue 🏦 #CashFlow 🚀 #Launch 🤖 #AI 🤖 #TradingFloorAI
Full market intelligence in bio.
The #MelloLondon line-up keeps growing 👀
Franchise Brands #FRAN, Odyssean IT #OIT, Ten Lifestyle #TENG, Trifast #TRI & Verici Dx #VRCI join the show.
Why not come & meet the management @MelloEventsUK on 17th & 18th Nov in Chiswick, West London?
Use code MLX25 for 25% off
#VRCI (£7m marketcap)
Precision medicine is steadily replacing healthcare’s old 'one-size-fits-all' playbook. Indeed by using genomic sequencing and protein biomarkers to understand a patient's specific condition, doctors can choose personalised therapies that improve efficacy and outcomes, while equally avoiding unnecessary treatment, toxicity and side effects.
Enter @VericiDx , whose kidney-transplant diagnostics already use multi-omic data and AI to help clinicians judge the risk of organ rejection and customise immunosuppression regimes.
Today the company added another potentially valuable income stream after becoming an Olink Certified Service Provider (part of Thermo Fisher's Life Sciences Solutions). In turn allowing its US laboratory to offer contract research (CRO) proteomics services for biomarker discovery, algorithm development, validation, clinical trials and diagnostics.
This is important because it not only creates a new fee-for-service revenue stream from pharma, biotech and other life-science customers, but also enhances the utilisation of its existing laboratory infrastructure.
What’s more, @VericiDx has already demonstrated this capability with a major pharmaceutical customer, analysing samples from a GLP-1 clinical trial using a custom protein panel.
COO Patti Connolly commenting: “Achieving Olink certification is an important milestone that reflects the strength of our laboratory team.”
In terms of the numbers, house broker @_singercm have a 1.3p/share target price based on FY26 revenue of $4.9m (+33%), including roughly $4.8m from c.2,100 Tutivia tests and $0.1m of services, gross profit of $3.5m, EBITDA of -$6.6m, PBT of -$7.4m and year-end net debt of around $0.1m.
The main headwind is cash burn (est $400k/month), albeit the June £2.6m gross fundraise at 0.35p/share, provides a cash runway to at least the end of 2026. In the FY’25 going concern statement, the Board recognised that #VRCI “will require additional capital before the end of 2026 and are taking steps to put in place such funding arrangements.”
Disclosure: @VericiDx is a @VOXmarkets client.
Not really a big believer in “follow the money” but follow the money #EEE
Someone just casually bought £1m worth of shares, so one would hope they’ve DTOR 📈😁
@DavidBurton1971
@Empiremetalsltd
#SVML #FIH #GENI #UOG #PALM #MPL #CTA #KEFI #GWMO #MATD #VRCI #MTC #AIM
@MagicSlon @miningcomau @diggersndealers @ozmining @RioTinto @bhp @CSIRO @CurtinUni @joannemidas @Empiremetalsltd C’mon Joanne😁
You know you want to furnish thousands of your readership with an updated article on #EEE
This is surely confirmation that your previous research article was bang on and a very savvy call from 2024 which you called at 9p (+366% & it’s only just the beginning) 👍🏼
@Share_Talk Shares Daily, Friday 31st July 2026
• Top Risers #OR6Y #HEAD #ROCK #AMGO #RCGH
• Top Fallers #CPX #VRCI #ORQP #AFP #OIIF
• Top Volume #PREM #FORG #CPX #SRES #ROCK
• Most Traded #RR #NWG #LSEG #BP #ULVR
The FTSE 100 finished Friday modestly lower after briefly reaching yet another all-time intraday record. The blue-chip index fell 29.22 points (0.3%) to close at 10,868.05, after earlier touching a fresh record high of 10,989.45. Despite the late retreat, the FTSE 100 still gained 1.2% over the week, while the FTSE 250 advanced 0.7%. 🔗 Read the full article here: https://t.co/AeJFSUSvDf
#VRCI
In this upbeat interview, CEO Sara Barrington of @VericiDx – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through last week’s ‘in line’ FY’25 results and positive outlook.
Disclosure: @VericiDx is a @VOXmarkets client
https://t.co/NjLj6EI4Co
Vox Markets Video Wrap - Keeping you informed with the latest company updates and investment insights from renowned stock market professionals
#HVO #POLB #MET1 #VRCI #QDE #ANCR #ITRK #BOOM #IQE #RPI #ITM #ALU #BRCK #SAGA #EZJ #CLX #HVO #GMS #PMI #AVG #CRPR #FDEV #DNLM #EXPN #PINE #DCC #JET2 #TUNE #SFT #SGE #WISE #VTY #ALU #AUTO #RMV #CHH #BBSN #TIDE #FRAS #DGE #ROSE #BKS
https://t.co/I7wqaYZdqc
#VRCI
After a challenging 3-4 years, prospects across the medical diagnostics industry appear to be improving as evidenced by increased M&A activity and rising valuations. Indeed only in Nov’25, Abbott Laboratories snapped up Exact Sciences, the maker of colon cancer test Cologuard for $23bn, or 6.2x EV/sales.
Sure these green shoots haven’t yet filtered down into UK small/microcap stocks, but I suspect this is only a matter of time.
Enter advanced kidney transplant diagnostics firm @VericiDx (Mrkcap £11m), who said in an upbeat FY’25 trading statement that it continued to deliver promising commercial traction, alongside inking a strategic agreement with Blue Cross Blue Shield Association (BCBS) of Illinois.
Revenues from its flagship kidney transplant test Tutivia jumped to $3m vs $0m in 2024. Granted this was slightly below expectations of £3.2m - albeit orders came in at $3.2m with volumes more than tripling to 1,173 units vs 334 LY.
More importantly though for investors, is that adoption is spreading across the US - as more doctors become aware of the Tutivia’s benefits, with 34 transplant centres now using the blood based diagnostic, representing 18% of kidney transplants.
Elsewhere, @VericiDx secured Medicare coverage, providing access to 68% of US transplant patients. Medicare approval is often the gatekeeper for broader acceptance, providing validation for clinicians and a benchmark for private insurers.
Such as today’s strategic agreement with BCBS of Illinois. Here Tutivia is now an in-network test for BCBS-covered patients in Illinois. Thus reducing the administrative friction for hospitals, lowering patient costs and enabling clinicians to use the service more routinely.
Moreover, BCBS operates as a federation with 118m members nationwide. Meaning by securing Illinois, Verici Dx has access to streamlined contracting processes with other BCBS entities, including large transplant markets like Texas. The agreement also spans multiple insurance categories — commercial, managed Medicaid and Medicare Advantage — broadening the reimbursable patient base from a single contract.
Finally, @VericiDx ended Dec’25 with net funds of $3.3m and $1.6m of receivables, supporting a cash runway into H2’26. Licence income fell to $0.8m ($3.3m LY) due to milestone timing with Thermo Fisher Scientific for their PTRA diagnostic (re Clarava).
CEO Sara Barrington commenting: “We are proud to have achieved substantial growth in FY25, reflected in the continued adoption of Tutivia and an increase in sales across the year. Whilst recognised Tutivia revenues of $3.0m were slightly behind market expectations for the full year, we continue to see strong testing volume acceleration beyond the $3.2m of orders received during the year. We are confident that our clinical and regulatory foundations will continue to show successful commercial traction across 2026 and beyond.”
Disclosure: @VericiDx is a @VOXmarkets client.
@DeItaone @SmackerAim I believe the only listed company in the UK to be working with AI Robotics is #SEED
Tiny mkt cap with plenty of cash and fair value double their mkt cap
Sounds too good to be true? Nope 🚀
@HaraldHadrada2 #HAMA #MIRI #VRCI
Last Seen Hashtags on Sotwe
نيج_عراقية
minichat(*)*******()()()****** filter:videos(***)
Seen from United States
ATM奴
Seen from Japan
faceabuse
Seen from Germany
eskisehiresc
Seen from Turkey
minichat #snapchat #teenageee
motherincestson
Seen from United States
seasoningsoysauce
Seen from Philippines
踩踏解压
Seen from Turkey
hidden cam sex
Seen from Turkey
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.3M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.3M followers
Bill Gates
@billgates
65.1M followers
Selena Gomez
@selenagomez
63M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers